Ignyte Bio

Ignyte Bio is a private, early-revenue stage company serving as a specialized supplier of human immune cell products and custom development services for the research market. Its core business model is providing high-quality, characterized biomaterials—such as antigen-specific T cells, monocytes, and dendritic cells—alongside consulting and custom product development services to accelerate immunology and oncology research. Led by a team with deep experience in cell therapy and biosourcing, the company aims to reduce the complexity and time researchers spend procuring biological materials. While not developing its own therapeutic pipeline, it supports the R&D efforts of pharmaceutical companies, CROs, and academic institutions.

Sourcing, processing, and characterization platform for primary human immune cells, including capabilities for cell isolation, expansion (e.g., iTregs, NK cells), and generation of antigen-specific T cells.

Ignyte Bio competes in the life science research tools market against large global suppliers (e.g., STEMCELL Technologies, ATCC, Lonza) and numerous smaller specialty biomaterial companies. Its differentiation is based on a focused immune cell catalog, deep characterization, a customer-centric 'scientist-led' service model, and custom development capabilities.